Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has announced a registered direct offering of 13,939,331 shares of common stock at $1.10 per share. The offering is expected to generate $15.3 million in gross proceeds, with approximately $0.8 million in placement agent fees and other expenses.
The offering, managed by sole placement agent Canaccord Genuity, is anticipated to close around March 5, 2025. The company plans to utilize the net proceeds for working capital and general corporate purposes. The securities are being offered through a previously declared effective Form S-3 registration statement.
Lucid Diagnostics (Nasdaq: LUCD), una società di diagnostica medica per la prevenzione del cancro in fase commerciale e sussidiaria di PAVmed, ha annunciato un'offerta diretta registrata di 13.939.331 azioni di azioni ordinarie a 1,10 $ per azione. Si prevede che l'offerta genererà 15,3 milioni di dollari di proventi lordi, con circa 0,8 milioni di dollari in commissioni per l'agente di collocamento e altre spese.
L'offerta, gestita dall'unico agente di collocamento Canaccord Genuity, dovrebbe chiudersi intorno al 5 marzo 2025. L'azienda prevede di utilizzare i proventi netti per il capitale circolante e per scopi aziendali generali. I titoli vengono offerti attraverso una dichiarazione di registrazione Form S-3 precedentemente dichiarata efficace.
Lucid Diagnostics (Nasdaq: LUCD), una empresa de diagnóstico médico en etapa comercial para la prevención del cáncer y subsidiaria de PAVmed, ha anunciado una oferta directa registrada de 13,939,331 acciones de acciones ordinarias a 1.10 $ por acción. Se espera que la oferta genere 15.3 millones de dólares en ingresos brutos, con aproximadamente 0.8 millones de dólares en comisiones por el agente de colocación y otros gastos.
La oferta, gestionada por el único agente de colocación Canaccord Genuity, se anticipa que cierre alrededor del 5 de marzo de 2025. La empresa planea utilizar los ingresos netos para capital de trabajo y propósitos corporativos generales. Los valores se ofrecen a través de una declaración de registro Form S-3 previamente declarada efectiva.
루시드 진단(Lucid Diagnostics) (Nasdaq: LUCD)은 상업적 단계의 암 예방 의료 진단 회사이자 PAVmed의 자회사로, 13,939,331 주의 보통주를 주당 1.10 달러에 등록된 직접 제안으로 발표했습니다. 이번 제안은 약 1530만 달러의 총 수익을 창출할 것으로 예상되며, 약 80만 달러의 배치 대행 수수료 및 기타 비용이 포함됩니다.
이번 제안은 단독 배치 대행사인 Canaccord Genuity에 의해 관리되며, 2025년 3월 5일경에 마감될 것으로 예상됩니다. 회사는 순수익을 운영 자본 및 일반 기업 목적에 사용할 계획입니다. 증권은 이전에 유효하다고 선언된 Form S-3 등록 명세서를 통해 제공됩니다.
Lucid Diagnostics (Nasdaq: LUCD), une entreprise de diagnostics médicaux en phase commerciale pour la prévention du cancer et filiale de PAVmed, a annoncé une offre directe enregistrée de 13 939 331 actions d'actions ordinaires à 1,10 $ par action. On s'attend à ce que l'offre génère 15,3 millions de dollars de produits bruts, avec environ 0,8 million de dollars de frais d'agent de placement et d'autres dépenses.
L'offre, gérée par l'agent de placement unique Canaccord Genuity, devrait se clôturer autour du 5 mars 2025. L'entreprise prévoit d'utiliser les produits nets pour le fonds de roulement et à des fins corporatives générales. Les titres sont offerts par le biais d'une déclaration d'enregistrement Form S-3 précédemment déclarée efficace.
Lucid Diagnostics (Nasdaq: LUCD), ein Unternehmen für medizinische Diagnostik zur Krebsprävention in der kommerziellen Phase und Tochtergesellschaft von PAVmed, hat ein registriertes Direktangebot von 13.939.331 Aktien zu einem Preis von 1,10 $ pro Aktie angekündigt. Es wird erwartet, dass das Angebot 15,3 Millionen Dollar an Bruttoeinnahmen generiert, wobei etwa 0,8 Millionen Dollar an Gebühren für den Platzierungsagenten und andere Ausgaben anfallen.
Das Angebot, das von dem alleinigen Platzierungsagenten Canaccord Genuity verwaltet wird, wird voraussichtlich um den 5. März 2025 abgeschlossen. Das Unternehmen plant, die Nettoerlöse für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Die Wertpapiere werden über eine zuvor für wirksam erklärte Registrierungserklärung Form S-3 angeboten.
- None.
- None.
Canaccord Genuity is acting as the sole placement agent for this offering.
The closing of the offering is expected to occur on or about March 5, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes.
The securities described above are being offered pursuant to a registration statement on Form S-3 (File No. 333-268560), which was declared effective by the Securities and Exchange Commission on December 6, 2022. A prospectus supplement relating to the securities being offered will be filed with the SEC. Electronic copies of the prospectus supplement and accompanying base prospectus included in the registration statement may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Canaccord Genuity LLC, Attention: Syndicate Department, One Post Office Square, Suite 3000,
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-15-3-million-registered-direct-offering-302391544.html
SOURCE Lucid Diagnostics
FAQ
How much is Lucid Diagnostics (LUCD) raising in their March 2025 offering?
What is the share price for LUCD's March 2025 registered direct offering?
When will LUCD's registered direct offering close?
How will Lucid Diagnostics use the proceeds from their 2025 offering?
Who is the placement agent for LUCD's March 2025 offering?
